A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes by Wallis, Stuart et al.
        
Citation for published version:
Wallis, S, Wolska, N, Englert, H, Posner, M, Upadhyay, A, Renne, T, Eggleston, I, Bagby, S & Pula, G 2021, 'A
peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with












If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 02. Jan. 2022

This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/JTH.15613
 This article is protected by copyright. All rights reserved
MR STUART  WALLIS (Orcid ID : 0000-0002-6908-9168)
DR NINA MALGORZATA WOLSKA (Orcid ID : 0000-0002-8982-9741)
DR GIORDANO  PULA (Orcid ID : 0000-0002-7769-1140)
Article type      : Original Article
TITLE: A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the 
interaction of platelets with leukocytes 
SHORT TITLE: A novel peptide antagonist of P-selectin
Stuart Wallis 1,2, Nina Wolska 2, Hanna Englert2, Mareike Posner1,3, Abhishek Upadhyay1, 
Thomas Renné2,4, Ian Eggleston5, Stefan Bagby1 and Giordano Pula2§.
1Departments of Biology and Biochemistry, University of Bath, United Kingdom; 2Institute 
of Clinical Chemistry and Laboratory Medicine, University Medical Center Eppendorf - 
Hamburg, Hamburg, Germany; 3Department of Life Sciences, Manchester Metropolitan 
University, Manchester, United Kingdom; 4Center for Thrombosis and Hemostasis (CTH), 
Johannes Gutenberg University Medical Center, Mainz, Germany, 5Department of 
Pharmacy and Pharmacology, University of Bath, United Kingdom. 
§Corresponding author: University Medical Center Eppendorf Hamburg (UKE), Institute 
for Clinical Chemistry and Laboratory Medicine, Martinistrasse 52, 20246 Hamburg, 
Germany. Email: g.pula@uke.de, Phone: +49 (0) 40 7410 54552.
ESSENTIALS










This article is protected by copyright. All rights reserved
 Here, we aimed to identity and characterise the Efb motif responsible for P-
selectin binding. 
 Efb68-87 binds platelets in a P-selectin-dependent manner without affecting their 
activation.
 Efb68-87 inhibits the formation of PLAs and the platelet-dependent stimulation of 
NETs in vitro.
ABSTRACT
Aims: P-selectin is a key surface adhesion molecule for the interaction of platelets with 
leukocytes. We have shown previously that the N-terminal domain of S. aureus 
extracellular fibrinogen-binding protein (Efb) binds to P-selectin and interferes with 
platelet-leukocyte aggregate formation. Here, we aimed to identify the minimal Efb motif 
required for binding platelets and to characterise its ability to interfering with the formation 
of platelet-leukocyte aggregates.
Methods and Results: Using a library of synthetic peptides, we mapped the platelet-
binding site to a continuous 20 amino acid stretch. The peptide Efb68-87 was able to bind 
to resting and, to a greater extent, thrombin-stimulated platelets in the absence of 
fibrinogen. Dot blots, pull-down assays and P-selectin glycoprotein ligand-1 (PSGL-1) 
competitive binding experiments identified P-selectin as the cellular docking site 
mediating Efb68-87 platelet binding. Accordingly, Efb68-87 did not bind to other blood cells 
and captured platelets from human whole blood under low shear stress conditions. Efb68-
87 did not affect platelet activation as tested by aggregometry, flow cytometry and 
immunoblotting, but inhibited the formation of platelet-leukocyte aggregates (PLAs). 
Efb68-87 also interfered with the platelet-dependent stimulation of neutrophil extracellular 
traps (NETs) formation in vitro. 
Conclusions: We have identified Efb68-87 as a novel selective platelet-binding peptide. 
Efb68-87 binds directly to P-selectin and inhibits interactions of platelets with leukocytes 
that lead to PLA and NET formation. As PLAs and NETs play a key role in 
thromboinflammation, Efb68-87 is an exciting candidate for the development of novel 
selective inhibitors of the proinflammatory activity of platelets.  
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INTRODUCTION
Our understanding of the role of platelets in vascular health has significantly progressed 
in recent years. In addition to platelets’ established role in haemostasis and thrombosis, 
their participation in inflammatory responses has become evident (1). The role of platelet 
pro-inflammatory activity for progression of cardiovascular disease has attracted 
considerable attention (2). In addition to their ability to release pro-inflammatory cytokines 
(3) and modulate the release of cytokines by leukocytes (4), platelets directly interact with 
leukocytes to form platelet-leukocyte aggregates (PLAs) (5). PLA formation has been 
shown to facilitate leukocyte homing and extravasation at the site of vascular injury, thus 
promoting inflammation (6). Inflammation is a key factor in vascular complications and 
cardiovascular diseases (7). PLAs are in fact increased in coronary syndromes, in the 
form of platelet-monocyte (8-12) and platelet-neutrophil complexes (13). PLA formation 
also increases as a consequence of coronary surgical intervention (14). Although CD40-
CD40L interactions (15) and the binding of the leukocyte receptor CD11b/CD18 (Mac-1) 
with either platelet glycoprotein receptor GPIBα (16) or platelet integrin αIIbβ3 (17) 
participate in the formation of PLAs, the interaction of platelet P-selectin and its 
physiological ligand P-selectin glycoprotein ligand-1 (PSGL-1) on leukocytes is critical for 
the heterotypic aggregation of these cell types (18). The interaction of platelets with 
neutrophils has particularly important pathophysiological consequences. Platelets can 
induce the formation of neutrophil extracellular traps (NETs) (19). While NETs have 
originally been described in host-defence processes (20), their role in the onset and 
progression of venous and arterial thrombosis has been shown in animal models and 
clinical studies (21-23). As for PLAs, the binding of P-selectin on platelets with PSGL-1 
on leukocytes is a critical step in NET formation (24).
Because of its role in the interaction of platelets with leukocytes, P-selectin has attracted 
increasing interest as a drug discovery target to develop pharmacobiological agents able 
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PLAs and NETs. The clinical potential of P-selectin inhibitors requires further 
investigation. We have shown previously that extracellular fibrinogen binding protein 
(Efb), a protein secreted by Staphylococcus aureus (S. aureus), directly binds P-selectin 
and inhibits its interaction with PSGL-1 (25). In contrast to numerous bacterial proteins 
that have been reported to positively modulate platelet function, Efb inhibits platelet 
activation and thrombus formation (26, 27), facilitating bacterial survival in the blood and 
aggravating infection (28). Efb comprises an N-terminal secretion signal, a N-terminal 
domain lacking structural organisation (Efb-N, residues Ser30-Thr104), and a tri-helical 
bundle C-terminal domain (Efb-C, residues Ile105-Lys165) (29) (Figure 1A). Efb-N 
includes two repeated motifs (residues Asn46-Pro67 and Asn77-Ala98) that are 
homologous to S. aureus coagulase repeats and that are part of fibrinogen binding sites 
comprising residues Ser30-Pro67 and Lys68-Ala98 (30). Efb-C plays an 
immunosuppressive role by interfering with the complement system (29, 31). In 
combination, Efb-N and Efb-C facilitate S. aureus escape from phagocytosis and 
increase S. aureus pathogenicity (32). In fact, S. aureus infections are significantly 
exacerbated in vivo in the presence of Efb (33).
In this study, we mapped the P-selectin-binding site in Efb-N using a peptide scanning 
approach. A 20 aa-peptide located within Efb-N between Lys68 and Glu87 bound P-
selectin. We show here that this peptide selectively binds platelets, without affecting their 
haemostatic function, and inhibits platelets’ ability both to complex with leukocytes to 
form PLAs and to induce NET formation. The therapeutic potential of this Efb-derived 
peptide to control thromboinflammation in cardiovascular patients will require further 
investigation.
METHODS
Peptide synthesis and labelling
All peptides were synthesised by KareBay Bio with the following sequences (purity >98%, 
























In order to fluorescently label lysine residues, synthetic peptides (or recombinant Efb-N30-
105) were coupled by direct reaction in 0.1 M sodium carbonate buffer with fluorescein 
isothiocyanate (FITC). The reaction mixture was incubated, with gentle agitation, at 4°C 
for 15 hours. Free FITC was eliminated by dialysis in PBS using a 500 Da MWCO cut-off 
membrane. 
 
Blood collection and platelet isolation
Procedures utilising human blood conformed to the principles outlined in the Declaration 
of Helsinki. Human blood was collected at the Institute of Clinical Chemistry and 
Laboratory Medicine (University Medical Center Eppendorf - Hamburg) after informed 
volunteers’ consent was given in written form. Sodium citrate (0.5% w/v) was used as an 
anticoagulant. Platelet-rich plasma (PRP) was separated from whole blood by 
centrifugation (250g, 17 minutes) and platelets were separated from PRP by a second 
centrifugation step (500g, 10 minutes) in the presence of prostaglandin E1 (PGE1, 40 
ng/mL) and indomethacin (10 μM). All centrifugations were performed with soft 
deceleration settings. Platelets were resuspended in modified Tyrode’s buffer at a density 
of 2×108 platelets/ml throughout the study. 
Flow cytometry (Efb binding) 
For isolated platelet binding, 107 platelets/ml were incubated in the presence or absence 
of 3 mg/ml fibrinogen and 0.2 U/ml thrombin for 10 minutes at room temperature. 1 µM 
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platelets followed by another 10 minute incubation. Platelet binding was assessed by flow 
cytometry using a FACSAria III (BD Biosciences).
Alternatively, 10 µM FITC-conjugated Efb peptide was incubated for 30 minutes at room 
temperature in heparin-anticoagulated (5 U/ml) human blood with CD42b/PE (#561854, 
BD Biosciences) and CD45/APC (#555745, BD Biosciences) antibodies. Cells were then 
fixed with 1% paraformaldehyde (PFA) for 15 minutes and binding was assessed by flow 
cytometry using a FACSCanto II (BD Biosciences).
Flow cytometry (activation/degranulation markers)
Heparin-anticoagulated (5 U/ml) human blood was preincubated with the relevant peptide 
for 15 minutes at 37°C. Platelets were activated with 1 U/ml thrombin for 15 minutes at 
37°C. Samples were then labelled with anti-CD42b/APC (#551061, BD Biosciences), 
anti-CD62P/PE (#550561, BD Biosciences), and PAC-1/FITC (#340507, BD Biosciences) 
antibodies for 15 minutes at room temperature. Samples were then fixed with 4% PFA for 
15 minutes at RT. Directly before measurement, the samples were diluted 1:1 with PBS 
and the fluorescence labelling was measured in 10,000 CD42b/APC-positive events, 
using a FACSCanto II flow cytometer (BD Biosciences). The mean fluorescence intensity 
(MFI) of CD42b/APC-positive events in the PE and FITC spectrum bands was analysed.
Isolated platelet fluorescence imaging
Coverslips were coated with 0.01% w/v poly-L-lysine and blocked with 0.1% w/v solution 
of BSA in PBS. Isolated platelets (resting, or activated in suspension with 10 µM TRAP6 
peptide for 5 minutes at 37°C) were dispensed onto the prepared coverslips at 0.5 x 107 
platelets/ml density and incubated for 1h at RT. Platelets were then fixed for 15 minutes 
in 4% PFA and stained with 2 μM solution of FITC-labelled peptide (Efb68-87 or Efb68-87 
(ctrl)) and, subsequently, with 1 U/ml phalloidin-rhodamine in PBS-Tween20 0.1% v/v. 
The coverslips were mounted onto the glass slides with Fluoromount mounting medium. 
Imaging was performed with a Leica TCS SP5 confocal microscope.
Dot blots
2 µg of Efb peptide (Karebay Bio, USA) was dotted onto nitrocellulose membrane and 
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being incubated in 0.1 ug/ml Fc-P-selectin (R&D Systems, # 137-PS-050) for 45 minutes. 
Subsequently, anti-P-selectin (Abcam, #ab182135) and IRDye® 800CW Donkey anti-
Rabbit IgG (Licor, #926-32213) antibodies were used for staining the membrane. Imaging 
was performed with a Licor Odyssey CLx scanner.
Pull-down experiments 
Efb68-87 or Efb68-87 (ctrl) was immobilised on CarboxyLink™ Coupling Resin (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. Peptide-conjugated resin 
was incubated with platelet lysates prepared by sonication from isolated platelet solution. 
After binding overnight at 4°C, the peptide complexed to platelet proteins was eluted from 
the resin according to the manufacturer’s instructions. Eluates were subsequently utilised 
for immunoblotting.
Immunoblotting
Platelet suspensions prepared as described above were stimulated in the presence of 1 
mM EGTA and lysed by adding lysis buffer (12.5 mM Tris, pH 8.3, 97 mM glycine, 2% 
sodium dodecyl sulphate (SDS), 0.5% dithiothreitol (DTT), 10% glycerol, and 0.01% 
bromophenol blue). Platelet proteins were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) membrane, 
and analysed by immunoblotting for P-selectin (Abcam, #ab182135), thrombospondin 1 
(Thermo Fisher Scientific, #MA5-13398), multimerin 1 (Santa Cruz Biotechnologies, #sc-
104427), actin (Merck Millipore #A5441), protein kinase C (PKC) phospho-substrates 
(#2261, Cell Signaling Technology) and phospho-Src (R&D Systems, # AF2685). 
Densitometry was performed using ImageJ 1.47v (Wayne Rasband, National Institute of 
Health, US) and presented as intensity ratio over actin staining (i.e. loading control).
Platelet aggregation
Platelets resuspended in modified Tyrode’s buffer at a density of 2×108 platelets/ml were 
stimulated using a Chrono-Log 490 4+4 aggregometer. Aggregation was induced with 0.1 
U/ml human thrombin or 3 µg/ml Horm collagen. Absorbance was measured for 10 
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Platelet adhesion/thrombus formation under flow
Vena8-Fluoro+ flow chambers were coated with 0.1mg/ml collagen or Efb68-87 or Efb68-87 
(ctrl). Blood was taken in 0.25% w/v citrate and 25 µM D-Phenylalanyl-Prolyl-Arginyl 
Chloromethyl Ketone (PPACK) and labelled with 1 μM 3,3'-dihexyloxacarbocyanine 
iodide (DiOC6) for 10 minutes at 37°C. As indicated in the text, the flow was set to 1000 
sec-1 (40 µl/minute) or 200 sec-1 (8 µl/minute). Quantification of platelet adhesion after 5 
minutes of flow was obtained by LED fluorescence microscopy (EVOS Fl) and image 
analysis using ImageJ 1.47v (Wayne Rasband, National Institute of Health, USA).   
PLA quantification
Heparin-anticoagulated (5 U/ml) human blood was treated with red blood cells (RBC) 
lysis solution (Miltenyi Biotec, Germany) and treated with Efb68-87 or Efb68-87 (ctrl) and 
collagen-related peptide (CRP) (1 µg/ml), TRAP6 (5 µM) and/or LPS from 
Staphylococcus aureus (1 µg/ml) to stimulate platelet-leukocyte aggregation. Anti-
CD42b/PE (#561854, BD Biosciences) and anti-CD45/APC (#555745, BD Biosciences) 
antibodies were used to stain platelets and leukocytes, respectively. Following fixation in 
1% w/v PFA, all samples were analysed using a FACSCanto II flow cytometer (BD 
Biosciences). PLAs were quantified as events positively stained for both markers (see 
Figure 5A) and their density was expressed as number of double-positive events over 
10,000 events.
NET visualisation and quantification
Neutrophils were isolated from human peripheral blood as previously described (34). 5 x 
104 neutrophils per well were seeded in 96-well plates and incubated at 37°C for 1 hour 
to allow cell adhesion. Platelet suspensions (1 x 107 platelets/ml) were incubated for 15 
minutes with 5μM Efb68-87 or Efb68-87 (ctrl) before incubation with TRAP6 (5 µM) for 15 
minutes to obtain platelet stimulation. Platelet suspensions were then added to the 
neutrophil monolayers (1 x 106 platelets/well) and incubated for 16 hours to induce NET 
formation. 0.1 µM phorbol-12-myristate-13-acetate (PMA) was added to positive control 
wells. Following fixation with 2% w/v PFA and staining with 1 µM Sytox Green (Life 
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Ts2R with Nikon DS-Fi3 camera) and quantified using a microplate reader (Tecan Spark 
10M) using 485 nmexc / 535 nmem. 
Statistical analysis
Data normality and homoscedasticity were tested with Shapiro-Wilk and Bartlett’s tests, 
respectively. For dual comparisons (i.e. WT vs 3KO) of normal/homoscedastic data, 
statistical analysis was performed by unpaired Student’s t-tests. Dual comparisons (i.e. 
WT vs 3KO) of non-normal/non-homoscedastic data were analysed by non-parametric 
Mann-Whitney test. One-way ANOVA with Bonferroni post-test was used for multiple 
comparison tests after testing that data are normal and homoscedastic. The software 
package GraphPad Prism Version 8.1.0 for Windows 64 bit was used for all statistical 
analyses. For the KD estimate, we utilised a sigmoidal regression model for one-site 
saturation binding within GraphPad Prism. Throughout the study, the results were 
expressed as the mean ± standard error (SEM). Differences were considered significant 
at P value < 0.05 (*), 0.01 (**) or 0.001 (***). 
RESULTS
Efb68-87 binds to platelets via P-selectin 
Binding experiments identified Efb68-87 (Figure 1A) as the minimal Efb sequence required 
to interact with platelets in the absence of fibrinogen (Figure 1B). Platelet stimulation with 
thrombin increased platelet-binding of Efb68-87 (Figure 1C). Efb68-99, a longer peptide 
including the newly-identified P-selectin-binding motif, displayed the ability to bind platelet 
upon platelet stimulation but not in unstimulated platelets. The addition of 3 mg/ml 
fibrinogen (i.e. physiological plasma concentration) stimulated binding of both Efb68-87 and 
Efb30-67 (Figure 1D), although it did not increase the level of Efb68-87 binding over the 
value for unstimulated platelets. Fluorescence microscopy (Figure 2A) and flow cytometry 
(Figure 2B) confirmed binding of FITC-Efb68-87 to unstimulated and stimulated platelets 
(TRAP6 and thrombin, respectively). The flow cytometry experiments showed that 
although the overall amount of bound Efb68-87 peptide is notably higher after platelet 
stimulation with thrombin (Figure 2B), the concentration-binding curve indicates a similar 
KD for the binding of Efb68-87 to resting and thrombin-stimulated platelets (5.7 μM and 3.4 
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(Figure 2C). Fc-P-selectin, a chimeric construct that allows effective suspension of P-
selectin in aqueous solution, comprising the extracellular domain of human P-selectin 
(i.e. residues 42-771) and human IgG1 residues 100-330, was immobilised on 
nitrocellulose membrane and treated with the library of FITC-labelled Efb peptides. As 
detected by fluorescence imaging of the membrane, Efb68-87, Efb68-99 and Efb-N (i.e. 
Efb30-105), bound to immobilised P-selectin. All other Efb- and scrambled control-peptides 
did not exhibit any binding activity to P-selectin. In addition, when immobilised on 
agarose beads, Efb68-87 pulled down P-selectin from platelet lysates, whereas it did not 
show any binding of thrombospondin-1 or multimerin-1, which were previously identified 
and confirmed as Efb-interacting proteins (25) (Figure 2D). The role of P-selectin in the 
binding of Efb68-87 was confirmed by competitive binding experiments using a 
recombinant chimeric construct of the physiological P-selectin ligand P-selectin 
glycoprotein ligand- (PSGL-1) (Figure 2E). In these experiments, the binding of FITC-
Efb68-87 was competitively inhibited by Fc-PSGL-1 (R&D Systems, # 3345-PS-050), 
confirming that P-selectin is the binding site for Efb68-87 on platelets.  
Efb68-87 selectively binds platelets and captures them from blood under flow
Amongst blood cells, P-selectin is selectively expressed in platelets. Therefore, we 
assessed whether Efb68-87 selectively binds platelets or might interact with other blood 
cells. Antibodies for platelet-specific (CD42b) and leukocyte-specific (CD45) markers 
were utilised in flow cytometry to identify platelets and leukocytes (white blood cells 
(WBCs) and red blood cells (RBCs)) (Figure 3A). FITC-Efb68-87 exclusively bound to 
platelets, while binding of WBCs and RBCs was negligible. We then used an adhesion 
assay under physiological flow to probe the stability of Efb68-87 binding to platelets, 
assessing whether Efb68-87 can be used to capture platelets from whole blood. Platelets 
bound to surfaces coated with Efb68-87 at venous (200 sec-1) (Figure 3B), but not arterial 
shear stress (1,000 sec-1) (Supplementary Figure 2). Interestingly, platelet adhesion and 
thrombus formation on fibrous collagen were not affected by Efb68-87 (Figure 3C), 
suggesting that Efb68-87 does not interfere with platelet function.  
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We investigated functional implications of Efb68-87 for platelet function. Platelet 
aggregation in response to the agonists collagen and thrombin was not affected by 
platelet pre-treatment with Efb68-87 compared to Efb68-87 (ctrl) (Figure 4A). The 
aggregation in response to secondary agonists ADP and U46619 (a stable analogue of 
thromboxane A2) was also unaffected by Efb68-87 (Supplementary Figure 3). In addition, 
platelet activation and degranulation were tested by flow cytometry. Data showed that the 
presence of Efb68-87 did not significantly change integrin αIIbβ3 activation (PAC1 antibody) 
or platelet degranulation (P-selectin externalisation) compared to Efb68-87 (ctrl) (Figure 
4B). Finally, potential effect of Efb68-87 incubation on intracellular platelets signalling was 
tested by immunoblotting (Figure 4C). Basal (resting platelets) and activated (thrombin-
stimulated platelets) levels of PKC activity and Src kinase activation in the presence of 
Efb68-87 and Efb68-87 (ctrl) were assessed using an anti-phospho PKC substrate antibody 
(detecting various proteins phosphorylated by classical platelet PKC isoforms α and β) 
and anti-phospho Src antibody (detecting Src in its active/phosphorylated form). 
Treatment with Efb68-87 did not affect activity of these two major platelet signalling 
pathways. Collectively, these results confirm that Efb68-87 binding does not interfere with 
platelet function.
Efb68-87 inhibits formation of platelet-leukocyte aggregates and reduces formation 
of neutrophil extracellular traps
The formation of heterotypic cellular complexes between platelets and leukocytes (i.e. 
platelet-leukocyte aggregates or PLAs) is an important driver of thromboinflammation. 
Since PLA formation depends on binding of platelet P-selectin to leukocyte PSGL-1, we 
tested whether Efb68-87 can block the formation of PLAs in human whole blood. PLAs 
were detected by flow cytometry as an event highly stained by both anti-CD42b and anti-
CD45 antibodies (Figure 5A). PLA levels were significantly increased by stimulation of 
whole blood with the GPVI receptor agonist CRP, but not the PAR1 agonist TRAP6 or the 
Toll-like receptor (TLR) agonist LPS used separately (Supplementary Figure 4). The 
study of Efb68-87‘s effect on PLA formation was performed with combined stimulation by 
CRP, TRAP6 and LPS. Substantial inhibition of PLA formation was observed at 1 μM or 
higher concentrations of Efb68-87 (Figure 5B). Since NET formation is another process 
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interferes with the stimulation of NET formation by platelets. Neutrophils isolated from 
human peripheral blood were allowed to adhere and were then treated with platelets. 
Resting platelets were compared to platelets treated with TRAP6 (5 µM). Stimulated 
platelets were able to induce a significant formation of NETs (Figure 6), which was 
inhibited by Efb68-87, but not with the control peptide for Efb68-87. The incubation of 
neutrophils with the above agonists in the absence of platelets did not lead to formation 
of NETs. Direct stimulation of NETs by neutrophil treatment with PMA was used as 
positive control, which was not affected by Efb68-87 (data not shown).
 
DISCUSSION
Discovery of their involvement in inflammatory responses and vascular degeneration has 
added an important new chapter in our understanding of the role of platelets in health and 
disease. In addition to the release of pro-inflammatory cytokines (35), the function of 
platelets in inflammatory processes involves the formation of PLAs, which mediate 
homing and extravasation of leukocytes at the site of vascular damage (6, 36). The 
interaction of P-selectin with PSGL-1 is the key molecular event for PLA formation (4). 
Other key surface receptors involved in PLA formation are activated in response to P-
selectin-PSGL-1 interaction. The activation of the leukocyte integrin αMβ2 (macrophage-1 
antigen or MAC-1) by P-selectin-PSGL-1 interaction, for example, is a key step in the 
formation of heterotypic complexes between platelets and leukocytes (37). In addition to 
linking inflammation with platelet activation and thrombus formation, and supporting the 
concept of thromboinflammation (38), the formation of PLAs has far-reaching 
consequences for cardiovascular health. Formation of heterotypic complexes between 
platelets and monocytes regulates the coagulation cascade through the upregulation of 
tissue factor (39), which exacerbates the thrombotic risk for patients with a variety of 
conditions, including COVID-19 (40).     
The P-selectin/PSGL-1 axis is therefore an attractive target for the development of novel 
antiinflammatory and vasculoprotective drugs. Although some reduction of PLAs can be 
achieved by traditional antiplatelet therapy (41), it is important to find strategies for 
achieving more comprehensive abatement of PLAs and avoiding the bleeding risk 
associated with existing antithrombotics. This makes the development of a safe and 
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medicine. Although several P-selectin antagonists have been described and proposed as 
candidates for drug development, there is currently no P-selectin inhibitor validated for 
clinical use. Recombinantly expressed vimentin (42), synthetic glycomimetics of the N-
terminus of PSGL-1 (43) and anti-P-selectin antibodies (44) have been characterised for 
their ability to compete with PLA formation in vitro and in vivo, while a promising small 
molecule failed to show any effect in vivo (45). The cost and pharmacokinetic properties 
of full recombinant proteins, large post-translationally modified peptides or antibodies 
make the search for novel candidate antagonists for P-selectin a relevant, timely and 
unresolved challenge for vascular drug discovery. In this study, we therefore followed a 
different approach. Based on our previous work showing that the bacterial protein Efb 
binds directly to P-selectin, inhibits its interaction with PSGL-1 and interferes with PLA 
formation (25), we set out to identify an Efb-derived peptide that retains the ability to bind 
P-selectin and inhibit PLA formation. 
The peptide we identified is Efb68-87, a twenty amino acid sequence from the N-terminal 
domain of Efb and part of one of two previously identified Efb binding sites for fibrinogen 
(30). Efb68-87 binding to platelets is not increased by addition of exogenous fibrinogen and 
is therefore fibrinogen-independent (Figure 1D). On the other hand, Efb30-67 interacts with 
platelets only in the presence of exogenous fibrinogen. Efb30-67 corresponds to the other 
previously identified fibrinogen binding site  (30). Interestingly, Efb68-87 shows similar 
binding affinity to resting and stimulated platelets, but the Efb68-87 binding capacity of 
platelets (i.e. amount of peptide bound per platelet) is significantly increased by 
stimulation (Figures 1B and 1C). This binding profile is compatible with a Binding site that 
is present at a low level on the surface of resting platelets but that undergoes an 
activation-dependent increase in level. This is characteristic of P-selectin levels which 
increase on the surface of platelets as a consequence of stimulation-dependent 
degranulation (i.e. migration to the cell periphery and fusion with the plasma membrane 
of P-selectin-rich alpha granules) (46). These data were supported by dot blot 
experiments, which confirmed direct binding of Efb68-87 to P-selectin (Figure 2C). Efb68-99 
was also able to bind to P-selectin in the dot blot experiments, although the level of 
staining was visibly lower. Further experiments would be required to assess whether the 
residues between Tyr88 and Ala99 may interfere with the binding of P-selectin. It is also 
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with multimerin-1 and thrombospondin-1. Since the interaction of Efb-N with multimerin-1 
and thrombospondin-1 was detected with the same approach utilised in this study (i.e. 
peptide conjugation and platelet protein pull-down), the most likely explanation is that the 
binding sites for these proteins map outside the Lys68-Glu87 portion of Efb-N. This 
observation emphasises the modular and multifunctional nature of Efb, with separate or 
overlapping binding sites for multiple target proteins. The modular multifunctionality of Efb 
could facilitate further biotechnological applications based on the use of this protein.
Efb68-87 represents a promising candidate for the development of a novel pharmacological 
agent with antiinflammatory or antithrombotic properties based on antagonism of P-
selectin and inhibition of PLA formation. This approach would have the advantage of 
leaving unaffected the haemostatic function of platelets, which should reduce or abolish 
any bleeding side effects. The use of current antiplatelet drugs from acetylsalicylic acid 
(ASA) to P2Y12 antagonists (such as Clopidogrel, Prasugrel and Ticagrelor) to integrin 
inhibitors (such as Abciximab or Tirofiban) is associated with an increase in 
haemorrhagic risk for patients (47, 48). This is likely to be the consequence of targeting a 
molecular pathway normally required for haemostasis (i.e. cyclooxygenases, ADP 
receptors or integrins). By targeting a surface adhesion molecule such as P-selectin that 
is not involved in healthy haemostatic responses, Efb68-87 would selectively diminish or 
abolish the contribution of platelets to the onset and/or progression of 
thromboinflammation, with little or no risk of causing haemorrhagic complications. 
We demonstrated in addition that Efb68-87 does not bind to other blood cells (Figure 3A) 
and that Efb68-87 does not interfere with the activation and function of platelets in 
response to physiological stimuli (Figure 4). Efb68-87 can therefore be used as a tool to 
selectively label platelets without affecting their responsiveness, which could find 
application in research and diagnostic laboratory practice. The ability to sequester 
platelets from whole blood (Figure 3B) could be investigated further to develop a novel 
platelet isolation method. Since Efb68-87 displayed increased binding to activated platelets 
(Figure 2B), it may be possible to develop a method to selectively capture activated 
platelets from whole blood. The selective reduction of the count of circulating activated 
platelets could find clinical application because an increase in circulating activated 
platelets is observed in several cardiovascular diseases and is proposed as a disease 
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In summary, we present here the identification and validation of Efb68-87, a novel P-
selectin antagonist derived from the N-terminal domain of the S. aureus protein Efb. In 
addition to confirming the selective binding to P-selectin, we have established the ability 
of Efb68-87 to interfere with PLA and platelet-induced NET formation in vitro without 
affecting platelet signalling and platelet functional responses. As the formation of PLAs 
and NETs is critical for the progression of vascular inflammation and its association with 
thrombotic complications, Efb68-87 has the potential to become a clinical tool for the 
treatment of conditions raging from major blood vessel atherosclerosis to microcirculatory 
dysfunction. Future clinical studies on this peptide may lead to the development of a 
novel treatment to help in the battle against thromboinflammatory conditions.  
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FIGURE LEGENDS
Figure 1. Synthetic Efb peptides bind human platelets. (A) Structure of Efb and the 
design of synthetic peptides representing different regions of the Efb N-terminal domain 
(amino acids 30-105). The signal peptide is shown in light blue, the first fibrinogen 
binding motif (Fg B1) in red, the second fibrinogen binding motif (Fg B2) in green. Efb 
peptide binding to resting (B), thrombin-stimulated (C) or fibrinogen-treated (D) platelets. 
1 µM FITC-labelled Efb or scrambled control peptides were incubated with isolated 
human platelets and their binding was assessed by flow cytometry. In C), thrombin 
stimulation was obtained with 0.1 u/ml human thrombin for 10 minutes, while in D) 
platelets were treated with 3 mg/ml fibrinogen for 10 minutes. Values are the median 
fluorescence intensity (MFI) from 10,000 events in five independent experiments (mean ± 
SEM). Statistical significance was assessed using one-way ANOVA with Bonferroni post-
hoc test; P-value < 0.05 (*), P-value < 0.01 (**), P-value < 0.001 (***).
Figure 2. Efb68-87 binding to platelet P-selectin. (A) Phalloidin-rhodamine (red, 1 U/ml) 
and FITC-labelled Efb68-87 (green, 2 μM) were used to stain human platelets fixed either 
before or after stimulation in suspension with TRAP6. FITC-labelled scrambled Efb68-87 
was used as control. Images are representative of five independent experiments. The 
scale bar indicated in white is 10 μm. (B) Using different concentrations of FITC-Efb68-87 
(0.1 – 100 μM), Efb68-87 binding affinity to resting and thrombin-stimulated platelets was 
assessed by flow cytometry. Data are % of the maximal binding values and are mean ± 
SEM from five independent experiments. (C) The direct interaction of Efb68-87 and P-
selectin was confirmed by dot blot. Fc-P-selectin was dotted onto individual nitrocellulose 
membranes and allowed to dry. After blocking with 5% w/v BSA, each FITC-Efb and 
FITC-scrambled Efb peptide (0.3 µg/ml of 68-87) was incubated on the membrane. 
Fluorescence images of the membranes were obtained with a ChemiDoc Scanner (Bio-
Rad) at 488 nmexc. The data are representative of six independent measurements. (D) 
Pull-down experiments performed with Efb68-87 conjugated to agarose beads confirmed 
P-selectin as the main candidate binding site for this peptide on platelets. Platelet lysate 
(lane 1), pull-downs with unconjugated beads (lane 2), pull-downs with beads conjugated 
with scrambled Efb68-87 (lane 3) and pull-downs with beads conjugated with Efb68-87 (lane 
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selectin, multimerin-1 or thrombospondin-1. The data are representative of five 
independent experiments. (E) Binding competition by Fc-PSGL-1. As described for (B), 
the binding of FITC-Efb68-87 to platelets was assessed by flow cytometry in the presence 
of different concentrations of Fc-PSGL-1 (0, 10 or 30 µM). Values are the median 
fluorescence intensity (MFI) from 10,000 events. Statistical significance was assessed 
using one-way ANOVA with Bonferroni post-hoc test: P-value < 0.05 (*), P-value < 0.01 
(**), P-value < 0.001 (***).
Figure 3. Efb68-87 binds to platelets in whole blood without interfering with collagen-
dependent thrombus formation. (A) CD42b/PE and CD45-APC antibodies were used 
to distinguish platelets (CD42b+), leukocytes (CD42b-, CD45+) and red blood cells 
(CD42b-, CD45-) from human blood by flow cytometry. FITC-Efb68-87 binding to each cell 
population was tested by flow cytometry. Data are mean ± SEM of the MFI values from 
10,000 events in 6 independent experiments. Statistical significance was assessed using 
one-way ANOVA with Bonferroni post-hoc test: P-value < 0.05 (*), P-value < 0.01 (**), P-
value < 0.001 (***). (B) Platelet adhesion to Efb68-87 under physiological flow. Platelet 
adhesion to Efb68-87 was tested at shear stress 200 sec-1 (venous) and 1,000 sec-1 
(arterial, not shown). In addition, (C) the effect of Efb68-87 (5 μM) on platelet adhesion and 
thrombus formation on collagen was tested (1,000 sec-1). Platelets in whole blood were 
fluorescently labelled with DiOC6 and their surface coverage was assessed by 
fluorescence imaging/densitometry analysis. Data presented are mean ± SEM of the 
surface coverage from 6 independent experiments. Statistical significance was assessed 
using the paired sample Student t-test (normality was assessed by Shapiro-Wilk test): P-
value < 0.05 (*), P-value < 0.01 (**), P-value < 0.001 (***).
Figure 4. Efb68-87 does not interfere with the normal functions of platelets. (A) 
Platelet aggregation induced by thrombin (0.1 U/ml) and collagen (10 μg/ml) was tested 
in the presence of 5 µM Efb68-87 or scrambled Efb68-87. Representative examples of 
aggregations from 4 independent experiments are shown and a bar graph shows mean ± 
SEM. No statistical significance was detected using the paired sample Student t-test. (B) 
Flow cytometry analysis of platelet activation and degranulation. Resting and thrombin-
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integrin αIIbβ3 activation (anti-PAC-1/FITC) in the presence of 5 µM Efb68-87 or scrambled 
Efb68-87. A representative forward scattering (FSC) / side scattering (SSC) dot plot of 
isolated platelets in the presence of Efb68-87 at resting (blue) and thrombin-stimulated 
(red) is also shown. The statistical significance between Efb68-87 and the control peptide 
was assessed using one-way ANOVA with Bonferroni post-test; P-value < 0.01 (**), P-
value < 0.001 (***), error bars represent mean ± SEM from 4 independent experiments. 
(C) Platelet signalling was studied by immunoblotting in the presence of Efb68-87 or Efb68-
87 ctrl peptides (10 μM). Platelets were activated with 0.1 U/ml thrombin (in the presence 
of 1mM EGTA to avoid platelet aggregation and so facilitate protein extraction). Following 
lysis and SDS-PAGE, lysates were immunoblotted for protein kinase C (PKC) 
phosphorylated substrates of classical protein kinase C (PKC) isoforms, phosphorylated 
Src and actin. Data were quantified by densitometry using ImageJ 1.47v, presented as 
intensity ratio over actin staining (i.e. loading control) and are mean ± SEM from five 
independent experiments. No statistical significance was detected using a paired sample 
Student t-test (normality was assessed by Shapiro-Wilk test). 
Figure 5. Efb68-87 inhibits the formation of PLAs in human whole blood. (A) Human 
blood was stimulated with CRP (1 µg/ml), TRAP6 (5 µM) and LPS from Staphylococcus 
aureus (1 µg/ml) for 30 minutes. Anti-CD42b/PE and anti-CD45/APC antibodies were 
used to stain platelets and leukocytes. PLAs were quantified in the top right quadrant of 
the PE/APC plot. (B) Where indicated, 0.1 - 100 μM Efb68-87 (or control peptide) was co-
incubated with the agonists. Data are the number of PLA per 10,000 events (i.e. blood 
cells) and represent mean ± SEM from five independent experiments. Statistical 
significance was assessed using one-way ANOVA with Bonferroni post-hoc test: P-value 
< 0.05 (*), P-value < 0.01 (**), P-value < 0.001 (***).
Figure 6. Efb68-87 inhibits the formation of platelet-induced NETs. 5 x 104/well 
neutrophils were seeded into 96-well plates and incubated at 37 ˚C for 1 hour. 5 µM 
Efb68-87, scrambled control peptide and vehicle solution were added to platelets before 
stimulation with TRAP6 (5 M). 1 x 106 platelets were added to each well. Negative control 
wells were prepared by adding either only neutrophils or only platelets with TRAP6 (5 M). 
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incubated for 16 hours at 37 °C with 5% CO2, before fixation in PFA and staining of 
NETs with Sytox Green. (A) Representative images of selected conditions from five 
independent experiments were obtained by fluorescence microscopy and are shown in 
the top panels. (B) The quantification of NET release was obtained by staining of the cell 
supernatants by fluorescence microplate reading after addition of Sytox green. Data are 
the mean ± SEM from five independent experiments. Statistical significance was 
assessed using one-way ANOVA with Bonferroni post-hoc test: P-value < 0.05 (*), P-
value < 0.01 (**), P-value < 0.001 (***).
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